Drugs Controller General of India (DCGI) Rajeev Singh Raghuvanshi on Thursday said bringing down regulatory intervention in the system and making it more simpler is a top priority for the organisation.
The DCGI is the apex authority in the country responsible for approval of licences of specified categories of drugs such as blood and blood products, intravenous fluids, vaccine and serum. It functions under the Directorate General of Health Services (DGHS) of the Ministry of Health.
Delivering a lecture at the CSIR-Indian Institute of Chemical Technology (IICT) here on the occasion of National Technology Day, he said there are currently many licences and interventions present in the system with a scope of making it much more simpler.
"...our (DCGI) current priorities for a couple of years, the first being, (we) want to reduce the regulatory intervention in the system. There are lot of licences and interventions. There is a scope of making it much more simpler. That is one area, where I have to work," he said.
Another priority area is to improve the subject experts committee where organisations like IICT can help in terms of bringing in new experts into the domain, he said.
Raghuvanshi, who was appointed to the top post in February this year, felt that regulation should be made more research centric.
Another priority area is to constantly keep increasing the footprint in digital space, he added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)